Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominique Talabot-Ayer

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Joint Bone Spine|November 28, 2012
Reply to Xie et al. about the article "Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis"Dominique Talabot-Ayer, Cem Gabay, Gaby Palmer
The Journal of Biological Chemistry|May 26, 2009
Interleukin-33 is biologically active independently of caspase-1 cleavageDominique Talabot-Ayer, Céline Lamacchia, Cem Gabay, et al.
The Journal of Investigative Dermatology|May 4, 2007
Type I IL-1 receptor mediates IL-1 and intracellular IL-1 receptor antagonist effects in skin inflammationGaby Palmer, Dominique Talabot-Ayer, Gürkan Kaya, et al.
Gene|August 12, 2022
Epigenetic remodeling of downstream enhancer regions is linked to selective expression of the IL1F10 gene in differentiated human keratinocytesDominique Talabot-Ayer, Alejandro Diaz-Barreiro, Ali Modarressi, et al.
Frontiers in Immunology|August 9, 2024
Interleukin-38 overexpression in keratinocytes limits desquamation but does not affect the global severity of imiquimod-induced skin inflammation in miceArnaud Huard, Emiliana Rodriguez, Dominique Talabot-Ayer, et al.
Plos One|March 20, 2018
The severity of imiquimod-induced mouse skin inflammation is independent of endogenous IL-38 expressionJennifer Palomo, Sabina Troccaz, Dominique Talabot-Ayer, et al.
Arthritis and Rheumatism|January 30, 2010
Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonistCéline Lamacchia, Gaby Palmer, Christian A Seemayer, et al.
Immunology|October 15, 2009
Expression and function of the NALP3 inflammasome in rheumatoid synoviumLaeticia Kolly, Nathalie Busso, Gaby Palmer, et al.
Journal of Leukocyte Biology|October 21, 2011
The mouse interleukin (Il)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promotersDominique Talabot-Ayer, Nicolas Calo, Solenne Vigne, et al.
Cytokine|June 1, 2005
Pre-interleukin-1alpha expression reduces cell growth and increases interleukin-6 production in SaOS-2 osteosarcoma cells: Differential inhibitory effect of interleukin-1 receptor antagonist (icIL-1Ra1)Gaby Palmer, Stéphanie Trolliet, Dominique Talabot-Ayer, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Joint Bone Spine|November 28, 2012
Reply to Xie et al. about the article "Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis"Dominique Talabot-Ayer, Cem Gabay, Gaby Palmer
The Journal of Biological Chemistry|May 26, 2009
Interleukin-33 is biologically active independently of caspase-1 cleavageDominique Talabot-Ayer, Céline Lamacchia, Cem Gabay, et al.
The Journal of Investigative Dermatology|May 4, 2007
Type I IL-1 receptor mediates IL-1 and intracellular IL-1 receptor antagonist effects in skin inflammationGaby Palmer, Dominique Talabot-Ayer, Gürkan Kaya, et al.
Gene|August 12, 2022
Epigenetic remodeling of downstream enhancer regions is linked to selective expression of the IL1F10 gene in differentiated human keratinocytesDominique Talabot-Ayer, Alejandro Diaz-Barreiro, Ali Modarressi, et al.
Frontiers in Immunology|August 9, 2024
Interleukin-38 overexpression in keratinocytes limits desquamation but does not affect the global severity of imiquimod-induced skin inflammation in miceArnaud Huard, Emiliana Rodriguez, Dominique Talabot-Ayer, et al.
Plos One|March 20, 2018
The severity of imiquimod-induced mouse skin inflammation is independent of endogenous IL-38 expressionJennifer Palomo, Sabina Troccaz, Dominique Talabot-Ayer, et al.
Arthritis and Rheumatism|January 30, 2010
Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonistCéline Lamacchia, Gaby Palmer, Christian A Seemayer, et al.
Immunology|October 15, 2009
Expression and function of the NALP3 inflammasome in rheumatoid synoviumLaeticia Kolly, Nathalie Busso, Gaby Palmer, et al.
Journal of Leukocyte Biology|October 21, 2011
The mouse interleukin (Il)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promotersDominique Talabot-Ayer, Nicolas Calo, Solenne Vigne, et al.
Cytokine|June 1, 2005
Pre-interleukin-1alpha expression reduces cell growth and increases interleukin-6 production in SaOS-2 osteosarcoma cells: Differential inhibitory effect of interleukin-1 receptor antagonist (icIL-1Ra1)Gaby Palmer, Stéphanie Trolliet, Dominique Talabot-Ayer, et al.
Pageof 4